Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen

References

• Plotkin SA. O.W., Vaccines. 4 ed. 2004: Saunders.
   Google Scholar
• Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776 - 9; http://dx.doi.org/10.1016/S0264-410X(03)00071-9; PMID: 12686093
   PubMed Web of Science ®Google Scholar
• Sheridan C. Next generation flu vaccine boosted by Chiron debacle. Nat Biotechnol 2004; 22:1487 - 8; http://dx.doi.org/10.1038/nbt1204-1487; PMID: 15583640
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499 - 509; http://dx.doi.org/10.1016/S1473-3099(04)01105-3; PMID: 15288823
   PubMed Web of Science ®Google Scholar
• Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176 - 85; http://dx.doi.org/10.1016/j.vaccine.2005.11.005; PMID: 16310896
   PubMed Web of Science ®Google Scholar
• Delaney JW, Fowler RA. 2009 influenza A (H1N1): a clinical review. Hosp Pract (Minneap) 2010; 38:74 - 81; PMID: 20469616
   PubMedGoogle Scholar
• Maritz J, Maree L, Preiser W. Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clin Chem Lab Med 2010; 48:11 - 21; http://dx.doi.org/10.1515/CCLM.2010.023; PMID: 20025556
   PubMed Web of Science ®Google Scholar
• Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009; 37:182 - 9; http://dx.doi.org/10.1016/j.biologicals.2009.02.014; PMID: 19297194
   PubMed Web of Science ®Google Scholar
• Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses 2008; 2:211 - 9; http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x; PMID: 19453397
   PubMed Web of Science ®Google Scholar
• Kissmann J, Joshi SB, Haynes JR, Dokken L, Richardson C, Middaugh CR. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. J Pharm Sci 2011; 100:634 - 45; http://dx.doi.org/10.1002/jps.22304; PMID: 20669328
   PubMed Web of Science ®Google Scholar
• McPherson CE. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 2008; 36:350 - 3; http://dx.doi.org/10.1016/j.biologicals.2008.08.001; PMID: 18804387
   PubMed Web of Science ®Google Scholar
• Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166 - 74; http://dx.doi.org/10.1016/0042-6822(85)90105-9; PMID: 4060580
   PubMed Web of Science ®Google Scholar
• Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706 - 9; http://dx.doi.org/10.1038/303706a0; PMID: 6190093
   PubMed Web of Science ®Google Scholar
• Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011; 7:313 - 21; http://dx.doi.org/10.4161/hv.7.3.14207; PMID: 21346417
   PubMed Web of Science ®Google Scholar
• Musiychuk K, Stephenson N, Bi H, Farrance CE, Orozovic G, Brodelius M, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respi Viruses 2007; 1:19 - 25; http://dx.doi.org/10.1111/j.1750-2659.2006.00005.x; PMID: 19453476
   PubMed Web of Science ®Google Scholar
• Perez-Iratxeta C, Andrade-Navarro MA. K2D2: estimation of protein secondary structure from circular dichroism spectra. BMC Struct Biol 2008; 8:25; http://dx.doi.org/10.1186/1472-6807-8-25; PMID: 18477405
   PubMed Web of Science ®Google Scholar
• Lin T, Wang G, Li A, Zhang Q, Wu C, Zhang R, et al. The hemagglutinin structure of an avian H1N1 influenza A virus. Virology 2009; 392:73 - 81; http://dx.doi.org/10.1016/j.virol.2009.06.028; PMID: 19628241
   PubMed Web of Science ®Google Scholar
• Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA. Composition and functions of the influenza fusion peptide. Protein Pept Lett 2009; 16:766 - 78; http://dx.doi.org/10.2174/092986609788681715; PMID: 19601906
   PubMed Web of Science ®Google Scholar
• Harrison SC. Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res 2005; 64:231 - 61; http://dx.doi.org/10.1016/S0065-3527(05)64007-9; PMID: 16139596
   PubMed Web of Science ®Google Scholar
• Harrison SC. Viral membrane fusion. Nat Struct Mol Biol 2008; 15:690 - 8; http://dx.doi.org/10.1038/nsmb.1456; PMID: 18596815
   PubMed Web of Science ®Google Scholar
• Shimizu S, Smith DJ. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 2004; 121:1148 - 54; http://dx.doi.org/10.1063/1.1759615; PMID: 15260652
   PubMed Web of Science ®Google Scholar
• Uedaira H, Uedaira H. Role of hydration of polyhydroxy compounds in biological systems. Cell Mol Biol (Noisy-le-grand) 2001; 47:823 - 9; PMID: 11728096
   PubMed Web of Science ®Google Scholar
• Lee JC, Timasheff SN. The stabilization of proteins by sucrose. J Biol Chem 1981; 256:7193 - 201; PMID: 7251592
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Kublin JG, Bodison SA, Nardin EH, Oliveira GA, et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002; 21:269 - 80; http://dx.doi.org/10.1016/S0264-410X(02)00468-1; PMID: 12450702
   PubMed Web of Science ®Google Scholar
• Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 1999; 18:531 - 9; http://dx.doi.org/10.1016/S0264-410X(99)00221-2; PMID: 10519944
   PubMed Web of Science ®Google Scholar
• Kaslow DC. Transmission-blocking vaccines. Chem Immunol 2002; 80:287 - 307; http://dx.doi.org/10.1159/000058850; PMID: 12058646
   PubMed Web of Science ®Google Scholar
• Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea - pigs: Toxoid precipitated with alum. J Pathol Bacteriol 1931; 34:267 - 75; http://dx.doi.org/10.1002/path.1700340214
   Google Scholar
• McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183:4403 - 14; http://dx.doi.org/10.4049/jimmunol.0900164; PMID: 19734227
   PubMed Web of Science ®Google Scholar
• Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17:479 - 87; http://dx.doi.org/10.1038/nm.2306; PMID: 21399646
   PubMed Web of Science ®Google Scholar
• Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010; 28:3588 - 94; http://dx.doi.org/10.1016/j.vaccine.2010.02.085; PMID: 20211692
   PubMed Web of Science ®Google Scholar
• Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005; 280:13406 - 14; http://dx.doi.org/10.1074/jbc.M500687200; PMID: 15684430
   PubMed Web of Science ®Google Scholar
• Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 2007; 96:547 - 57; http://dx.doi.org/10.1002/jps.20762; PMID: 17080408
   PubMed Web of Science ®Google Scholar
• FDA. U.S. CFR - Code of Federal Regulations Title 21. [cited 2011 December 9]; Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.15.
   Google Scholar
• Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011; 7:Suppl 41 - 50; http://dx.doi.org/10.4161/hv.7.0.14561; PMID: 21266846
   PubMed Web of Science ®Google Scholar
• Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. J Pharm Sci 2005; 94:1893 - 911; http://dx.doi.org/10.1002/jps.20410; PMID: 16052555
   PubMed Web of Science ®Google Scholar
• Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci 2003; 92:1805 - 20; http://dx.doi.org/10.1002/jps.10439; PMID: 12949999
   PubMed Web of Science ®Google Scholar
• Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 2011; http://dx.doi.org/10.1002/jps.22618; PMID: 21647886
   PubMed Web of Science ®Google Scholar
• Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008; 26:2930 - 4; http://dx.doi.org/10.1016/j.vaccine.2008.03.045; PMID: 18440103
   PubMed Web of Science ®Google Scholar